Lidocaine patch and hypafix

PreclinicalSmall molecule

Lidocaine patch and hypafix is one of 40 small molecule programs targeting Shoulder pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Shoulder PainActive, not recruiting

Shoulder PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Shoulder Pain

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Savella

AbbVie

Approved

1 3

Prostigmin

Merck & Co.

Approved

1 4

Xylocaine

MMEDRx USA, Inc.

Approved

5 5

Medrol

Pfizer

Approved

—6

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 7

Kenalog

BBassett Healthcare

Approved

2 8

Naropin

FFresenius Kabi Oncology Ltd.

Approved

2 9

Atropen

FFresenius Kabi Oncology Ltd.

Approved

1 10

Duragesic

CCephalon

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Shoulder pain1 trial

Effect of Lidocaine Patch for Shoulder Pain in Laparoscopic Cholecystectomy

Completed·—·N/A·NCT02827136·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lidocaine patch and hypafix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lidocaine patch and hypafix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lidocaine patch and hypafix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ajou University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAjou University School of Medicine

Lidocaine patch and hypafix

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Shoulder pain1 trial

References

Drug Info

Quick Facts

Related News